The compound, named PROLENSA, was developed by recently acquired ISTA Pharmaceuticals.
“The PROLENSA filing is an important step towards bringing safe, effective and meaningful medical advances to medical professionals and their patients,” said Marvin Garrett, vice president of U.S. regulatory affairs, quality assurance and compliance for Bausch + Lomb, in the release. “It’s also a timely example of the progress we continue to make on critical D&R programs as we work to bring together the best of ISTA Pharmaceuticals and Bausch + Lomb.”
Related Articles on FDA Clearances:
Medtronic Receives Expanded FDA Clearance for Pillar Palatal Implant System
St. Jude Receives FDA Clearance for Ultrasound Catheter
Kimberly-Clark Health Care Receives FDA Clearance for Sterilization Wrap Portfolio
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.